Our Phase II & III Capabilities
Many of our sites have participated in research for 10+ years. Our partnerships provide access to CA residents throughout the State with nearly 20 partnerships in over 50+ locations. We help provide access to a diverse patient population, including minority groups that otherwise go unrepresented in research.
Rapid Start
- Central IRB.
- Contract and budget response within 48 hours.
- Regulatory documents completed in parallel.
- Often able to complete start-up within 2 weeks.
- Dedicated Call Center team to assist with enrolling.
Capabilities
- FibroScans, ultrasounds, X-rays, PBMC, local labs, and much more available at many locations.
- Nearby access to liver biopsy, MRI-PDFF, DEXA, CT-Scans, and much more.
- Efficient prescreening process.
- Experience with telemedicine, virtual, and hybrid trials.
Quality Control
- Our Internal quality team provides QC on all ICF and critical documents.
- eRegulatory and eSource offer increased quality and efficiency.
- eDocuments available for sponsor review 24/7.
Our Diverse Data
Race/Ethnicity | US Census (%) (2019) | US Patients (%) in Clinical Trials | FOMAT Enrollment (%) |
White / Caucasian | 76.5 | 84.2 | 36% |
Black/African-American | 13.4 | 7.3 | 1% |
Asian | 5.9 | 3.4 | 5% |
Native Hawaiian/ Pacific Islander | 0.2 | 0.1 | 0.3% |
Native-Indian/Native Alaskan | 1.3 | 0.1 | 0.3% |
More than 1 race | 2.7 | 0.0 | 3% |
Other/Unknown | - | 3.7 | 7.4% |
Hispanic/Latino | 18.3 | 2.8 | 47% |